How reliable are staging and grading in periodontitis and what do they mean for clinical decision-making?

What does “Grading: Progression Risk” mean for me as a patient?

When it comes to grading: progression risk, the research landscape is clearer than many think. Here’s what the current studies actually show.

The Grading system complements the staging with a prognostic dimension, differentiating three grades (A, B, C) that estimate the progression risk of gum disease (periodontitis). The primary criterion is radiographic bone loss relative to the patient’s age; secondary modifiers include smoking and diabetes mellitus (Tonetti et al. 2018). Grade A corresponds to slow progression, Grade B to moderate, and Grade C to rapid progression. The BSP guideline (West et al. 2021) integrates grading into therapy planning by recommending more intensive and closely monitored care concepts for Grade C.

Hashim et al. (2025) report that patients with Stage IV, Grade C gum disease (periodontitis) showed the strongest improvements through combined periodontal and orthodontic therapy, especially when the orthodontic intervention was initiated early after regenerative therapy. This suggests that grading is not only prognostic but also relevant for choosing the timing of therapy. However, these results are based on a limited number of heterogeneous studies, and prospective comparative studies stratifying outcomes by grade are currently lacking.

The Cochrane review by Liu et al. (2019) indirectly highlights the relevance of grading for systemic comorbidities. The included primary prevention study examined people with gum disease and metabolic syndrome—a patient group that would typically be assigned Grade B or C according to the grading system, as diabetes and obesity are considered risk modifiers. However, the scientific evidence was insufficient to draw causal conclusions.

A key issue with the grading is the radiological determination of the progression rate. This requires longitudinal X-rays over several years, which are often not available in practice. Without comparative images, the progression rate can only be estimated indirectly based on the ratio of bone loss to age, leading to systematic misestimations in older patients with cumulative bone loss. The guideline by West et al. (2021) does not explicitly address this issue, and the included reviews do not offer a solution for this diagnostic dilemma.

Methodologically, it is important to note that the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nonetheless, the direction of the effect remains consistent across different study types.

For applicability to the German-speaking healthcare context, it is relevant that a significant portion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in payment structures, treatment culture, and patient access can influence effect sizes without invalidating the basic assertion.

The grading influences clinical decisions at two levels: first, it determines the intensity of therapy—Grade C patients receive more frequent follow-up intervals and often adjunctive systemic antibiotics. Second, it modulates prognosis assessment, such as whether a severely compromised tooth should be retained or extracted.

In practice, the most common challenge is distinguishing between Grade A and B in patients without clear risk modifiers and without longitudinal radiographic data. Here, standard Grade B is assigned, which can result in a significant proportion of patients receiving an undifferentiated moderate risk assessment. This weakens the discriminative power of the system.

In everyday practice, this means that scientific evidence does not provide a uniform answer but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be considered in the decision-making process.

What does this mean for you? Grading uncertainties must be transparently communicated.

As a patient, it is important to know that no examination method is perfect. Research shows under what conditions a method is most reliable and when you should seek a second opinion.

How do scientists arrive at these conclusions? They do not just evaluate one study but look at many studies simultaneously. This allows them to recognize whether a result was random or consistently confirmed. In this case, the findings are based on 8 scientific works from different countries and research groups.

What does "Impact on Therapy Decisions" mean for me as a Patient?

A point that often causes uncertainty is the impact on therapy decisions. However, science has made important progress in recent years.

The BSP guideline (West et al. 2021) defines a four-stage treatment pathway that is directly coupled to the staging system. Stage 1 includes behavioral changes, risk factor control, and professional mechanical plaque reduction. Stage 2 involves subgingival instrumentation, which is recommended for all stages, potentially supplemented by adjunctive measures. Stage 3 encompasses surgical interventions (Access Flap, Resection Procedures, regenerative surgery), primarily indicated at Stages III and IV after Stage 2 with remaining deep pockets. Stage 4 is lifelong supportive periodontal therapy.

The 15 systematic reviews underlying the EFP guideline provide the scientific basis for individual therapy stages. For subgingival instrumentation (stage 2), Teughels et al. (2020) found consistent clinical improvements in probing depth and attachment level (Suvan et al. 2020). For adjunctive systemic antibiotics at stage 2, Hashim et al. (2025) reported a statistically significant but clinically modest additional benefit, with the guideline limiting their use to young patients with grade C and generalized stage III periodontitis to minimize resistance issues.

Hashim et al. (2025) broaden the perspective on interdisciplinary treatment concepts, showing that orthodontic measures can be clinically meaningful in stages III and IV after successful periodontal pre-treatment and regenerative therapy. The authors emphasize that reduced orthodontic forces and close interdisciplinary coordination are prerequisites for safe outcomes. Long-term follow-ups of up to ten years documented stable results, although study quality varied and no RCTs were available.

For systemic health effects of periodontal therapy, the Cochrane review by Liu et al. (2019) provides no robust scientific evidence. From only two RCTs with high risk of bias and very low research result reliability (GRADE), neither a benefit nor harm from periodontal therapy regarding cardiovascular endpoints could be derived. This underscores that the primary therapeutic goal for periodontal treatment is to improve periodontal outcomes, while systemic benefits are biologically plausible but not substantiated by intervention studies.

The guideline explicitly emphasizes that therapy planning depends not only on the stage but also on individual response to previous stages. A one-size-fits-all assignment of stage to treatment is not recommended; instead, reevaluation and escalation are performed after each stage if there is inadequate response. This step-care model better reflects clinical reality than rigid algorithms.

Methodologically, the included studies vary significantly in study design, follow-up period, and population selection. This heterogeneity limits comparability of results and explains why pooled effect estimates must be interpreted with caution. Nonetheless, the direction of the effect is consistent across different study types.

For applicability to the German-speaking healthcare context, it is relevant that a significant portion of scientific evidence comes from Anglo-American or Scandinavian health systems. Differences in reimbursement structure, treatment culture, and patient access may affect effect sizes without invalidating the basic assertion.

The staged treatment pathway provides clinicians with a clear decision framework. The key clinical implication is that surgical interventions should only occur after completion and reevaluation of non-surgical therapy—unless specific complexity factors (such as deep vertical defects or furcation involvement grade III) necessitate an earlier surgical intervention.

The scientific evidence from Hashim et al. (2025) shows that orthodontic treatment in advanced gingival disease (periodontitis) is not contraindicated but requires stringent prerequisites: stable periodontal conditions after pre-treatment, reduced forces, and close periodontal monitoring during the orthodontic phase.

In practice, this means that no single method is perfect. Research indicates under what conditions a method is most reliable and when you should seek a second opinion.

What makes these results reliable? In medical research, the more independent studies that come to the same conclusion, the stronger the statement. The type of study and the number of participants also play a crucial role. Large controlled trials with many participants provide more reliable results than small surveys.